GALMED PHARMACEUTICALS LTD (GLMD) Fundamental Analysis & Valuation

NASDAQ:GLMD • IL0011313900

Current stock price

0.741 USD
-0.04 (-5.63%)
At close:
0.7201 USD
-0.02 (-2.82%)
After Hours:

This GLMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. GLMD Profitability Analysis

1.1 Basic Checks

  • In the past year GLMD has reported negative net income.
  • In the past year GLMD has reported a negative cash flow from operations.
  • GLMD had negative earnings in each of the past 5 years.
  • In the past 5 years GLMD always reported negative operating cash flow.
GLMD Yearly Net Income VS EBIT VS OCF VS FCFGLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • GLMD has a Return On Assets (-40.31%) which is in line with its industry peers.
  • The Return On Equity of GLMD (-45.52%) is better than 65.18% of its industry peers.
Industry RankSector Rank
ROA -40.31%
ROE -45.52%
ROIC N/A
ROA(3y)-63.37%
ROA(5y)-66.75%
ROE(3y)-76.34%
ROE(5y)-80.13%
ROIC(3y)N/A
ROIC(5y)N/A
GLMD Yearly ROA, ROE, ROICGLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GLMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLMD Yearly Profit, Operating, Gross MarginsGLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GLMD Health Analysis

2.1 Basic Checks

  • GLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLMD Yearly Shares OutstandingGLMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
GLMD Yearly Total Debt VS Total AssetsGLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • GLMD has an Altman-Z score of -12.23. This is a bad value and indicates that GLMD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -12.23, GLMD is doing worse than 76.98% of the companies in the same industry.
  • There is no outstanding debt for GLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.23
ROIC/WACCN/A
WACCN/A
GLMD Yearly LT Debt VS Equity VS FCFGLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • GLMD has a Current Ratio of 7.98. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 7.98, GLMD is doing good in the industry, outperforming 70.99% of the companies in the same industry.
  • GLMD has a Quick Ratio of 7.98. This indicates that GLMD is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of GLMD (7.98) is better than 71.57% of its industry peers.
Industry RankSector Rank
Current Ratio 7.98
Quick Ratio 7.98
GLMD Yearly Current Assets VS Current LiabilitesGLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GLMD Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GLMD will show a very strong growth in Earnings Per Share. The EPS will grow by 31.88% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.57%
EPS Next 2Y32.83%
EPS Next 3Y21.42%
EPS Next 5Y31.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLMD Yearly Revenue VS EstimatesGLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2029 2030 10M 20M 30M 40M
GLMD Yearly EPS VS EstimatesGLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

1

4. GLMD Valuation Analysis

4.1 Price/Earnings Ratio

  • GLMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLMD Price Earnings VS Forward Price EarningsGLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLMD Per share dataGLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • GLMD's earnings are expected to grow with 21.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.83%
EPS Next 3Y21.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GLMD Dividend Analysis

5.1 Amount

  • GLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GLMD Fundamentals: All Metrics, Ratios and Statistics

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (4/10/2026, 8:27:37 PM)

After market: 0.7201 -0.02 (-2.82%)

0.741

-0.04 (-5.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-20
Inst Owners1.35%
Inst Owner Change0%
Ins Owners0.99%
Ins Owner Change0%
Market Cap4.89M
Revenue(TTM)N/A
Net Income(TTM)-8.70M
Analysts43.33
Price TargetN/A
Short Float %0.27%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.84%
Min EPS beat(2)25.58%
Max EPS beat(2)40.09%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS2.9
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.31%
ROE -45.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.37%
ROA(5y)-66.75%
ROE(3y)-76.34%
ROE(5y)-80.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.98
Quick Ratio 7.98
Altman-Z -12.23
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y63.57%
EPS Next 2Y32.83%
EPS Next 3Y21.42%
EPS Next 5Y31.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.54%
OCF growth 3YN/A
OCF growth 5YN/A

GALMED PHARMACEUTICALS LTD / GLMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GALMED PHARMACEUTICALS LTD?

ChartMill assigns a fundamental rating of 2 / 10 to GLMD.


What is the valuation status of GALMED PHARMACEUTICALS LTD (GLMD) stock?

ChartMill assigns a valuation rating of 1 / 10 to GALMED PHARMACEUTICALS LTD (GLMD). This can be considered as Overvalued.


Can you provide the profitability details for GALMED PHARMACEUTICALS LTD?

GALMED PHARMACEUTICALS LTD (GLMD) has a profitability rating of 1 / 10.


Can you provide the financial health for GLMD stock?

The financial health rating of GALMED PHARMACEUTICALS LTD (GLMD) is 6 / 10.